Lithium succinate

Drug Profile

Lithium succinate

Alternative Names: Efadermin; Efalith

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Louis Widmer; Scotia Holdings [CEASED]
  • Class Small molecules; Succinates
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Seborrhoeic dermatitis
  • Discontinued Atopic dermatitis; Human papillomavirus infections; Mycoses

Most Recent Events

  • 02 Apr 2015 The product is approved for Seborrhoeic dermatitis in EU countries and South Africa
  • 26 Jan 2012 Withdrawn for Seborrhoeic dermatitis in Ireland (Topical)
  • 22 Jan 2002 No-Development-Reported for Human papillomavirus infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top